Merck and Co Inc (MRK)

[DewDiligence]

Keytruda/chemo showed statsig-better PFS than chemo alone in second-line TNBC for the subgroup with PD-L1>=10% in the KEYNOTE-355 study:

https://www.businesswire.com/news/home/20200212005254/en/Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Combination-Chemotherapy-Met-Primary

PFS was not statsig for the (larger) subgroup in the same trial with PD-L1>=1% or (presumably) in the entire ITT group.

The PFS hazard ratios will be revealed at a medical conference. The OS data are not yet mature.

Note: Roche’s Tecntriq with chemo is approved in first-line TNBC.